Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 27, 2013Presentados hoy en EuroPCR los datos provisionales del programa clínico REDUCE-HTN
Boston Scientific Corporation (NYSE: BSX) ha anunciado hoy los datos provisionales del programa clínico REDUCE-HTN, que demuestran una reducción significativa y duradera de la tensión arterial...
-
May 27, 2013Interimdaten aus dem klinischen Programm REDUCE-HTN wurden heute auf dem EuroPCR präsentiert
Boston Scientific Corporation (NYSE: BSX) hat heute Interimdaten aus dem klinischen Programm REDUCE-HTN präsentiert, die eine signifikante und nachhaltige Reduktion des Blutdrucks bei Patienten...
-
May 22, 2013
Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for...
-
May 22, 2013
Boston Scientific Corporation (NYSE: BSX) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial evaluating the performance and safety of...
-
May 22, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair® Bronchial Thermoplasty (BT)...
-
May 21, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair® Bronchial Thermoplasty (BT)...
-
May 21, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair® Bronchial Thermoplasty (BT)...
-
May 21, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair® Bronchial Thermoplasty (BT)...
-
May 17, 2013
"We are pleased to present a particularly rich and diversified set of data this year at EuroPCR," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific. "The primary endpoint...
-
May 17, 2013
Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris. "We are pleased to present a particularly rich and diversified set...